Hatch-Waxman 101: Safe Harbor
Event summary
Cooley lawyers discuss the development and current scope of Safe Harbor under 35 U.S.C. § 271(e)(1), and the practical impact of Safe Harbor considerations on Hatch-Waxman and other pharmaceutical patent litigation. We also address its impacts on freedom to operate and licensing considerations during product development and fundraising.
For more information or to request access to the program recording, please email email Maria Russo.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.